Dihexa

Common side effects:

• Mild headaches during initial administration
• Temporary jitteriness or overstimulation
• Gastrointestinal discomfort
• Injection site reactions if administered subcutaneously

Rare or serious side effects:

• Potential theoretical risk of accelerating existing tumor growth due to c-Met activation
• Unpredictable interactions with other dopaminergic or serotonergic agents
• Severe lethargy or paradoxical fatigue

Hepatocyte growth factor (HGF) activation serves as the primary mechanism of action for the Dihexa peptide. It functions as a highly potent, blood-brain barrier-permeable mimetic of HGF, directly binding to and dimerizing the c-Met receptor Benoist et al., 2014. This receptor activation triggers a cascade of intracellular signaling events, most notably the PI3K/AKT signaling pathway, which is crucial for neuronal survival and synaptic plasticity Sun et al., 2021. By amplifying this specific pathway, the peptide effectively bypasses the traditional Angiotensin IV receptor system to exert its neurotrophic effects. Synaptic network expansion occurs rapidly following c-Met receptor activation by Dihexa. The peptide stimulates the localized formation of dendritic spines, which are the primary structural foundations for excitatory synapses in the mammalian brain. This structural remodeling directly correlates with enhanced long-term potentiation, providing a molecular basis for the profound cognitive benefits and memory recovery observed in neurodegenerative disease models Wright et al., 2015.

Discovery and development of Dihexa originated at Washington State University under the guidance of researchers investigating the renin-angiotensin system. Scientists sought to create an Angiotensin IV analog that possessed both high metabolic stability and the ability to cross the blood-brain barrier effectively. Through extensive structural modifications, they synthesized Dihexa, which demonstrated a synaptogenic potency orders of magnitude greater than brain-derived neurotrophic factor (BDNF). Regulatory status currently classifies Dihexa strictly as a research chemical rather than an approved pharmaceutical drug. It has not received evaluation or approval from the FDA for human consumption or medical treatment. Ongoing preclinical studies continue to explore its safety profile and therapeutic viability for conditions like Alzheimer's disease and traumatic brain injury, keeping it confined to laboratory and experimental settings.